Lantern Pharma Inc. has announced its upcoming annual meeting of stockholders, set for December 1, 2026. This meeting will be conducted via live audio webcast, allowing stockholders to participate from anywhere in the world. The decision to hold the meeting online underscores the company's commitment to transparency and shareholder engagement.
The filing, submitted on October 19, 2026, includes a definitive proxy statement outlining the details of the meeting. Lantern Pharma, a Texas-based company, operates in the pharmaceutical preparations sector, focusing on the development of innovative cancer therapies.
Background
Lantern Pharma Inc. is classified under the SIC code 2834, which pertains to pharmaceutical preparations. The company is publicly traded on the Nasdaq under the ticker symbol LTRN. Lantern Pharma is recognized for its efforts in advancing cancer treatment through its proprietary drug development platform.
What the Filing Says
The definitive proxy statement filed with the SEC details the logistics of the upcoming annual meeting. It states, "You are cordially invited to attend the 2026 Annual Meeting of Stockholders... to be held at 11:00 a.m. Eastern time, on Tuesday, December 1, 2026." The meeting will provide stockholders with the opportunity to submit questions and vote electronically.
Impact
This event may affect Lantern Pharma's stockholders, who will have the chance to engage with the company's leadership and influence key decisions. The online format of the meeting is expected to enhance participation, making it easier for stockholders to be involved in the company's governance.
What's Next
As the date of the annual meeting approaches, additional filings may provide further details regarding the agenda and proposals to be discussed. For now, the filing does not specify what happens next.